www.fdanews.com/articles/123021-glaxosmithkline-boosts-arthritis-drugs-deal-with-galapagos-to-291-million
GlaxoSmithKline Boosts Arthritis-Drugs Deal With Galapagos to $291 Million
December 16, 2009
GlaxoSmithKline, the U.K.-based pharma giant with North American
headquarters in Research Triangle Park, has extended its agreement with Belgian-drug maker Galapagos to develop new arthritis drugs.
Triangle Business Journal
Triangle Business Journal